Influence of scan duration on the accuracy of β-amyloid PET with florbetaben in patients with Alzheimer's disease and healthy volunteers

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 40, Issue 2, 2013, Pages 238-244

  Tiepolt, Solveig ^a   Barthel, Henryk ^a   Butzke, Daniel ^a   Hesse, Swen ^a   Patt, Marianne ^a   Gertz, Hermann Josef ^a   Reininger, Cornelia ^b   Sabri, Osama ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b BAYER PHARMA AG   (Germany)

Author keywords

Amyloid; Alzheimer's disease; Florbetaben; PET; Scan duration; Scan time

Indexed keywords

AMYLOID BETA PROTEIN; FLORBETABEN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; EFFECT SIZE; FEMALE; HUMAN; MALE; MULTICENTER STUDY; NEUROIMAGING; OPEN STUDY; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; BRAIN; BRAIN MAPPING; CASE-CONTROL STUDIES; DIAGNOSTIC IMAGING; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; OBSERVER VARIATION; POSITRON-EMISSION TOMOGRAPHY; RANDOM ALLOCATION; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; STILBENES; TIME FACTORS;

EID: 84874052859     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-012-2268-8     Document Type: Article

References (15)

1. Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Arch Neurol. 2011;68:398-403.
2. Selkoe DJ. The molecular pathology of Alzheimer's disease. Neuron. 1991;6(4):487-98.
3. Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Buerger K, et al. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and Healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011;10:424-35.
4. Herholz K, Ebmeier K. Clinical amyloid imaging in Alzheimer's disease. Lancet Neurol. 2011;10:667-70.
5. Lister-James J, Pontecorvo MJ, Clark C, Joshi AD, Mintun MA, Zhang W, et al. Florbetapir F-18: a histopathologically validated beta-amyloid positron emission tomography imaging agent. Semin Nucl Med. 2011;41:300-4.
6. Vallabhajosula S. Positron emission tomography radiopharmaceuticals for imaging brain beta-amyloid. Semin Nucl Med. 2011;41:283-99.
7. Barthel H, Luthardt J, Becker G, Patt M, Hammerstein E, Hartwig K, et al. Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer's disease and healthy controls. Eur J Nucl Med Mol Imaging. 2011;38:1702-14.
8. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002;15(1):273-89.
9. Drzezga A. Amyloid-plaque imaging in early and differential diagnosis of dementia. Ann Nucl Med. 2010;24:55-66.
10. Suotunen T, Hirvonen J, Immonen-Räihä P, Aalto S, Lisinen I, Arponen E, et al. Visual assessment of [(11)C]PIB PET in patients with cognitive impairment. Eur J Nucl Med Mol Imaging. 2010;37:1141-7.
11. Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011;305:275-83.
12. Wolk DA, Grachev ID, Buckley C, Kazi H, Grady MS, Trojanowski JQ, et al. Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. Arch Neurol. 2011;68:1398-403.
13. Kukull WA, Larson EB, Reifler BV, Lampe TH, Yerby MS, Hughes JP. The validity of 3 clinical diagnostic criteria for Alzheimer's disease. Neurology. 1990;40:1364-69.
14. Jellinger K, Danielczyk W, Fischer P, Gabriel E. Clinicopathological analysis of dementia disorders in the elderly. J Neurol Sci. 1990;95:239-58.
15. Cselényi Z, Jönhagen ME, Forsberg A, Halldin C, Julin P, Schou M, et al. Clinical validation of 18F-AZD4694, an amyloid-β-specific PET radioligand. J Nucl Med. 2012;53:415-24.